Targeting inflammation in depression using Minocycline: a patient stratification approach using peripheral inflammatory biomarkers and MRI

Ki vehet részt

• Being male or female depressed patients (aged 18-65); 2. Having a current DSM-V diagnosis of nonpsychotic major depressive disorder confirmed by SCID; 3. Being non-responder to a current SSRI for at least 8 weeks, and historically to one other SSRI; 4. Being in stable antidepressant therapy for at least 8 weeks; 5. Being tolerant to the current SSRI; 6. Accepting Minocycline treatment; 7. Having CPR level> 2 mg/L; 8. Having signed and dated an informed consent to participate in the study; 9. Having no contraindications to receive treatment with Minocycline

Ki nem vehet részt

• Having active suicidal ideation; 2. Having a primary diagnosis of bipolar disorder, obsessive-compulsive disorder, eating disorder, PTSD; 3. Having a history of substance/alcohol abuse; 4. Having received tetracycline therapy within the previous 2 months; 5. Having a history of sensitivity to this class of drugs; 6. Having acute infections or an autoimmune or inflammatory disorder; 7. Having CRP>20 mg/L, as indicates acute infection or other major pathology; 8. Being sensitive to Minocycline; 9. Having a history of severe allergy or hypersensitivity to drugs; 10. Being hypersensitive to the active substance, to other tetracyclines or to any of the excipients; 11. Having severe renal failure; 12. Having hepatic dysfunction; 13. Being pregnant and in lactation; 14. (for MRI) Having pacemakers, electromechanical devices, ferromagnetic vascular clips, cochlear implants, stapedial prostheses, ferromagnetic foreign bodies, sickle cell anemia